Recent Updates on Management of Diffuse Large B-Cell Lymphoma

EP. 1: Treating Newly Diagnosed Patients With DLBCL

July 12th 2021

Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.

EP. 2: Treatment Considerations in DLBCL

July 12th 2021

Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.

EP. 3: DLBCL: Approaching CNS Prophylaxis

July 19th 2021

A panel of experts explain how they approach CNS prophylaxis in DLBCL.

EP. 4: Outlook for CNS Lymphoma

July 19th 2021

David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.

EP. 5: Managing Relapsed DLBCL

July 26th 2021

Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.

EP. 6: Recommendations for Second-Line Therapy in DLBCL

July 26th 2021

Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.

EP. 7: Data From the L-MIND Trial

August 2nd 2021

Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).

EP. 8: DLBCL: Approaches to Treating Patients Ineligible for Transplant

August 2nd 2021

Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.

EP. 9: Newer Approvals for Previously Treated DLBCL

August 9th 2021

A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.

EP. 10: Recommendations for CAR T-Cell Therapy in R/R DLBCL

August 9th 2021

Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.

EP. 11: Evaluating CAR T Therapies in Lymphoma

August 16th 2021

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

EP. 12: Optimal Approaches to Bridging Therapy in DLBCL

August 16th 2021

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

EP. 13: Treating Patients Post CAR T Therapy

August 23rd 2021

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

EP. 14: Looking at the Big Picture in DLBCL 

August 23rd 2021

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

EP. 15: Exploring Emerging Data in DLBCL 

August 23rd 2021

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.